Amoxicillin, clarithromycin, and omeprazole based targeted nanoparticles for the treatment of H. pylori

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of drug targeting (Print)

• Publication date

  2009-04-01

• Fields of study

  Medicine, Materials Science, Chemistry

• Identifiers
  DOI 10.1080/10611860902718649PMID 19241256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori.

  2008cited by this paper
• Clarithromycin- and omeprazole-containing gliadin nanoparticles for the treatment of Helicobacter pylori.

  2008cited by this paper
• Triple therapy-based targeted nanoparticles for the treatment of Helicobacter pylori

  2008cited by this paper
• Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy.

  2007cited by this paper
• Clarithromycin based oral sustained release nanoparticulate drug delivery system

  2006cited by this paper
• In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin.

  2005cited by this paper
• Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model

  2004cited by this paper
• Effect of potassium chloride and cationic drug on swelling, erosion and release from κ-carrageenan matrices

  2004cited by this paper
• Floating microspheres bearing acetohydroxamic acid for the treatment of Helicobacter pylori

  2003cited by this paper
• Site-specific drug delivery of acetohydroxamic acid for the treatment of H. pylori

  2003cited by this paper
• Receptor Mediated Targeting of Lectin Conjugated Gliadin Nanoparticles in the Treatment of Helicobacter pylori

  2003cited by this paper
• A New Approach in Gastroretentive Drug Delivery System Using Cholestyramine

  2003cited by this paper
• The Stool Antigen Test for Detection of Helicobacter pylori after Eradication Therapy

  2002cited by this paper
• Helicobacter pylori: the challenge in therapy

  2002cited by this paper
• ABC of the upper gastrointestinal tract: Epidemiology and diagnosis of Helicobacter pylori infection.

  2001cited by this paper
• Current Concepts And Drug Therapy Of Helicobacter Pylori Infection

  1999influential reference
• vaccine in The Netherlands . persons vaccinated with inactivated poliovirus Poliovirus-specific immunoglobulin A in

  1997cited by this paper
• Treatment of Helicobacter pylori infection: a review.

  1997influential reference
• Changes in Helicobacter pylori ultrastructure and antigens during conversion from the bacillary to the coccoid form

  1996influential reference
• Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.

  1996cited by this paper
• In vitro antibacterial activity of omeprazole and its selectivity for Helicobacter spp. are dependent on incubation conditions

  1996cited by this paper
• Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine.

  1995cited by this paper
• Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state

  1995cited by this paper
• Intragastric Distribution of Ion‐exchange Resins: a Drug Delivery System for the Topical Treatment of the Gastric Mucosa

  1995cited by this paper
• Effect of Chitosan on the Permeability of Monolayers of Intestinal Epithelial Cells (Caco-2)

  1994influential reference
• Gastroduodenal mucosal protection.

  1993cited by this paper
• Pathogenic mechanisms of Helicobacter pylori.

  1993cited by this paper
• Local gastric and serum amoxicillin concentrations after different oral application forms

  1993cited by this paper
• Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation.

  1992cited by this paper
• Clarithromycin and omeprazole for Helicobacter pylori.

  1992cited by this paper
• Difference in expression of Helicobacter pylori gastritis in antrum and body.

  1992cited by this paper
• Lectin Typing of Helicobacter pylori

  1990cited by this paper
• Bacterial adhesion and disease activity in Helicobacter associated chronic gastritis.

  1990cited by this paper
• Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study.

  1989cited by this paper
• Pathogenetic implications of ultrastructural findings in Campylobacter pylori related gastroduodenal disease.

  1988cited by this paper
• Interaction of bacteria and fungi with lectins and lectin-like substances.

  1981cited by this paper
• What should be called a lectin?

  1980cited by this paper

• Revolutionizing Nanovaccines: A New Era of Immunization

  2025cites this paper
• Discovery of 2-(4-Ureido-piperidin-1-yl)-4-morpholinothieno [3,2-D] Pyrimidines as Orally Bioavailable Phosphoinositide-3-Kinase Inhibitors with In Vitro and In Vivo Antitumor Efficacy in Triple-Negative Breast Cancer.

  2025cites this paper
• Advance Helicobacter pylori Eradication: Current Therapeutic Strategies and the Potential of Lipid-Based Nanocarriers for Targeting Receptors.

  2025cites this paper
• Nanotechnology-based approaches to tackle bacterial infections.

  2025cites this paper
• Recent drug delivery systems targeting the gut-brain-microbiome axis for the management of chronic diseases.

  2025cites this paper
• The role of miRNAs in pathogenesis, diagnosis, and therapy of Helicobacter pylori infection, gastric cancer-causing bacteria: Special highlights on nanotechnology-based therapy.

  2025cites this paper
• Targeting the Tumor Microbiota in Cancer Therapy Basing on Nanomaterials

  2025cites this paper
• Cannabidiol-Based Prodrugs: Synthesis and Bioevaluation.

  2024cites this paper
• Insights of probiotics as an alternative medicine for cancer therapy, mechanism, and applications

  2024cites this paper
• Targeted nanotherapeutics for the treatment of Helicobacter pylori infection

  2024cites this paper
• Advances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy.

  2024cites this paper
• ADME/PK Insights of Crocetin: A Molecule Having an Unusual Chemical Structure with Druglike Features

  2024cites this paper
• Helicobacter pylori infection in humans and phytotherapy, probiotics, and emerging therapeutic interventions: a review

  2024cites this paper
• Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy

  2023cites this paper
• Chitosan Nanoparticles for Gastroesophageal Reflux Disease Treatment

  2023cites this paper
• Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.

  2023cites this paper
• Omeprazole and H2S releasing agents encapsulated in chitosan nanoparticles to enhance healing process against indomethacin-induced gastric ulcer model

  2023cites this paper
• Modulating gut microbiota using nanotechnology to increase anticancer efficacy of the treatments

  2023cites this paper
• Gastric acid powered micromotors for combined-drug delivery to eradiate helicobacter pylori

  2023cites this paper
• Preparation, characterization, and evaluation of antibacterial and cytotoxic activity of chitosan-polyethylene glycol nanoparticles loaded with amoxicillin as a novel drug delivery system

  2023cites this paper
• Delivering macrolide antibiotics to heal a broken heart - and other inflammatory conditions.

  2022cites this paper
• Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy

  2021cites this paper
• Application of Polymeric Nanocarriers for Enhancing the Bioavailability of Antibiotics at the Target Site and Overcoming Antimicrobial Resistance

  2021cites this paper
• Microbe-Based Therapies for Colorectal Cancer: Advantages and Limitations.

  2021cites this paper
• Biomimetic Strategies for enhancing synthesis and delivery of antibacterial nanosystems.

  2021cites this paper
• A supercritical assisted process for the production of amoxicillin-loaded liposomes for antimicrobial applications

  2020cites this paper
• Novel chitosan-based pH-responsive lipid-polymer hybrid nanovesicles (OLA-LPHVs) for delivery of vancomycin against methicillin-resistant Staphylococcus aureus infections.

  2020cites this paper
• Eradication of Helicobacter pylori: the power of nanosized formulations.

  2020cites this paper
• Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors

  2020cites this paper
• Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice.

  2020cites this paper
• Chitosan Inhibits Helicobacter pylori Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells

  2020cites this paper
• Sialic acid-based strategies for the prevention and treatment of Helicobacter pylori infection: Emerging trends in food industry

  2020cites this paper
• Gut microbiota targeted nanomedicine for cancer therapy: Challenges and future considerations

  2020cites this paper
• SYSTEMATIC REVIEW ON APPLICATION OF NANOTECHNOLOGY IN WOUND HEALING AND ULCER

  2020cites this paper
• marine drugs Chitosan Inhibits Helicobacter pylori Growth and Urease Production and Prevents Its Infection of Human Gastric Carcinoma Cells

  2020cites this paper
• The biological challenges and pharmacological opportunities of 1

  2019cites this paper
• Nanotechnology intervention of the microbiome for cancer therapy

  2019cites this paper
• Ureido-modified carboxymethyl chitosan-graft-stearic acid polymeric nano-micelles as a targeted delivering carrier of clarithromycin for Helicobacter pylori: Preparation and in vitro evaluation.

  2019cites this paper
• The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery

  2018cites this paper
• Coating Nanoparticles with Gastric Epithelial Cell Membrane for Targeted Antibiotic Delivery against Helicobacter pylori Infection

  2018cites this paper
• Formulation and development of colon-targeted mucopenetrating metronidazole nanoparticles

  2017cites this paper
• Nanosized devices as antibiotics and antifungals delivery: past, news, and outlook

  2017cites this paper
• Innovative Methods and Applications in Mucoadhesion Research.

  2017cites this paper
• Nanoantimicrobials: Activity, Benefits, and Weaknesses

  2017cites this paper
• COMPARATIVE MUCOPENETRATION ABILITY OF METRONIDAZOLE LOADED CHITOSAN AND PEGYLATED CHITOSAN NANOPARTICLES

  2017cites this paper
• Ultrahigh antibacterial efficacy of meropenem-loaded chitosan nanoparticles in a septic animal model.

  2017cites this paper
• Current applications of nanoparticles in infectious diseases.

  2016cites this paper
• Nanotherapeutics: From Laboratory to Clinic

  2016cites this paper
• Development of novel chitosan nanocomposites as a controlled drug release system for Helicobacter pylori treatment

  2016cites this paper
• Role of Novel Drug Delivery Systems in Stomach Specific Anti-Helicobacter Pylori Therapy

  2015cites this paper
• Preparation, characterization and pharmacokinetics evaluation of clarithromycin-loaded Eudragit® L-100 microspheres

  2015cites this paper
• Modification of drug delivery to improve antibiotic targeting to the stomach.

  2015cites this paper
• CD4+ Foxp3+ regulatory T‐cell number increases in the gastric tissue of C57BL/6 mice infected with Helicobacter pylori

  2015cites this paper
• Organic and Inorganic Nanoparticles for Prevention and Diagnosis of Gastric Cancer.

  2015cites this paper
• Nanoparticle approaches against bacterial infections.

  2014cites this paper
• Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections.

  2014cites this paper
• The potential utility of chitosan micro/nanoparticles in the treatment of gastric infection

  2014influential citation
• Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.

  2014cites this paper
• Eradication of Helicobacter pylori: Past, present and future.

  2014cites this paper
• Recent advances in ligand targeted therapy

  2012cites this paper
• Simultaneous Estimation Of Amoxicillin, Tinidazole And Omeprazole In Microsphere Formulation By RP-HPLC

  2012cites this paper
• N-Acyl Ciprofloxacins: Synthesis, Antibacterial Activity and Effects on Molecular Loading of Poly(vinyl benzoate) Nanoparticles

  2012cites this paper
• Mucoadhesive and muco-penetrating delivery systems for eradication of Helicobacter pylori

  2012influential citation
• Physicochemical and anti-bacterial performance characterization of clarithromycin nanoparticles as colloidal drug delivery system.

  2011cites this paper
• Helicobacter pylori infection in India from a western perspective.

  2010cites this paper
• Nanoscale particle therapies for wounds and ulcers.

  2010cites this paper
• Review of antimicrobial and antioxidative activities of chitosans in food.

  2010cites this paper
• Helicobacter pylori infection in India from a western perspective

  2010cites this paper
• Helicobacter pylori: Current treatment An important challenge for gastroenterology

  2009cites this paper